Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO® (faricimab injection) Pre-Filled Syringe (PFS) is now publicly funded though the Ontario Drug Benefit Program.1 ...

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, ...

The introduction of five upcoming registrational readouts for 2026 is a new forward-looking highlight. Product net sales and operating profit both increased meaningfully quarter-over-quarter, as did ...

Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However, access ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 ...

On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in ...

Investing.com -- Argenx (EBR: ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...

Argenx (($ARGX)) has held its Q3 earnings call. Read on for the main highlights of the call. Argenx’s recent earnings call painted a picture of ...

State Key Laboratory for Quality and Safety of Agro-Products, Key Laboratory of Biotechnology in Plant Protection of MARA, Zhejiang Key Laboratory of Green Plant Protection, Institute of Plant ...